GoodRx Now Offers 40% More Savings on Nearly 200 Medications at Walgreens
Lower prices offer added savings on top medications for heart disease, men’s health, mental health and more
SANTA MONICA, Calif., September 11, 2023--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced a new initiative at Walgreens to reduce prices on nearly 200 prescription medications by an average of 40%, with even greater savings available for select medications. Consumers can now purchase many popular prescriptions at Walgreens for less than $15 for a 30-day fill, without any deductibles, restrictions, paperwork, approvals or quantity limitations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230911100555/en/
GoodRx offers more savings on common prescriptions at Walgreens. (Graphic: Business Wire)
The new lower prices include medications for many health concerns, including heart disease and mental health, as well as categories often not covered by insurance, such as acne, insomnia, men’s health, and weight loss.
"Americans shouldn’t have to jump through hoops to be able to afford their medications," said Jim Sheninger, Pharmacy Strategy Officer of GoodRx. "Walgreens has been part of our network since nearly the beginning, enabling us to offer their customers lower prices on the most commonly prescribed medications to make it even easier for people to save money. We believe everyone deserves affordable healthcare, and this initiative will help more Americans access the treatment they need."
The following is a sample list of the most common prescriptions available now for lower prices at Walgreens with a GoodRx coupon:
Medication | Previous Price | Lower Price | % Savings |
Heart Disease | |||
Amlodipine | $21.83 | $6.69 | 69% |
Lisinopril | $12.91 | $7.27 | 44% |
Ezetimibe | $34.99 | $20.51 | 41% |
Atorvastatin | $21.99 | $13.75 | 37% |
Men’s Health | |||
Finasteride | $71.58 | $16.88 | 76% |
Vardenafil | $149.62 | $38.53 | 74% |
Tadalafil (Cialis) | $29.99 | $16.90 | 44% |
Sildenafil | $25.99 | $19.69 | 24% |
Mental Health | |||
Escitalopram | $34.15 | $14.05 | 59% |
Bupropion XL | $29.99 | $15.62 | 48% |
Fluoxetine | $25.50 | $13.49 | 47% |
Sertraline | $19.99 | $13.84 | 31% |
For years, GoodRx has provided Walgreens customers with significant cost savings on their medications. Now, for a limited time, medications are even more affordable for the millions of customers Walgreens serves each day at its nearly 9,000 retail locations.
With rising medication prices and high inflation making it difficult for many Americans to manage their healthcare costs, GoodRx aims to make it easier than ever for Walgreens customers to save on prescriptions and adhere to treatment plans.
To search prescription savings at Walgreens and compare prices, consumers can visit www.GoodRx.com/Walgreens.
About GoodRx
GoodRx is a leading resource for healthcare savings and information that makes healthcare affordable and convenient for all Americans. We offer consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. Since 2011, we have helped consumers save over $60 billion and are one of the most downloaded medical apps over the past decade.
GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the "SEC") and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding consumer savings and the benefits of our offerings to consumers and at any pharmacies. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, our reliance on a limited number of industry participants, the competitive nature of our industry, risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cyber-security and the important factors discussed in the sections entitled "Risk Factors" in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, and our other filings with the Securities and Exchange Commission. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911100555/en/
Contacts
GoodRx Media Contact
Lauren Casparis
press@goodrx.com
